Jones Financial Companies Lllp raised its position in Pfizer Inc. (NYSE:PFE – Free Report) by 2.6% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,638,683 shares of the biopharmaceutical company’s stock after purchasing an additional 117,340 shares during the quarter. Jones Financial Companies Lllp owned 0.08% of Pfizer worth $112,666,000 as of its most recent SEC filing.
Other large investors also recently added to or reduced their stakes in the company. Van Hulzen Asset Management LLC boosted its position in shares of Pfizer by 3.1% during the second quarter. Van Hulzen Asset Management LLC now owns 40,772 shares of the biopharmaceutical company’s stock worth $982,000 after buying an additional 1,229 shares during the period. Park Place Capital Corp raised its holdings in shares of Pfizer by 40.0% in the 2nd quarter. Park Place Capital Corp now owns 30,792 shares of the biopharmaceutical company’s stock valued at $741,000 after buying an additional 8,791 shares during the period. Peak Asset Management LLC lifted its stake in Pfizer by 78.0% during the 2nd quarter. Peak Asset Management LLC now owns 29,704 shares of the biopharmaceutical company’s stock worth $715,000 after acquiring an additional 13,017 shares in the last quarter. Fiduciary Financial Advisors acquired a new position in Pfizer during the 2nd quarter worth about $121,000. Finally, Manning & Napier Advisors LLC boosted its holdings in Pfizer by 2.2% during the 2nd quarter. Manning & Napier Advisors LLC now owns 79,351 shares of the biopharmaceutical company’s stock valued at $1,934,000 after acquiring an additional 1,688 shares during the period. 68.36% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
A number of brokerages have issued reports on PFE. Royal Bank Of Canada upgraded shares of Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price target on the stock in a research note on Tuesday, June 9th. Bank of America dropped their price objective on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a report on Friday, July 10th. Wall Street Zen raised shares of Pfizer from a “hold” rating to a “buy” rating in a research note on Saturday, August 1st. BMO Capital Markets reduced their target price on shares of Pfizer from $34.00 to $30.00 and set an “outperform” rating on the stock in a report on Monday, July 13th. Finally, Weiss Ratings cut shares of Pfizer from a “hold (c)” rating to a “hold (c-)” rating in a research report on Monday, August 17th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $28.28.
Pfizer Trading Up 2.0%
NYSE PFE opened at $28.53 on Wednesday. Pfizer Inc. has a 52 week low of $23.58 and a 52 week high of $28.75. The firm has a 50 day moving average of $25.39 and a two-hundred day moving average of $26.27. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71. The stock has a market capitalization of $162.60 billion, a PE ratio of 37.54 and a beta of 0.34.
Pfizer (NYSE:PFE – Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, beating analysts’ consensus estimates of $0.68 by $0.09. The business had revenue of $15.03 billion for the quarter, compared to analyst estimates of $14.40 billion. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The company’s revenue was up 2.6% on a year-over-year basis. During the same period last year, the business earned $0.78 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, research analysts expect that Pfizer Inc. will post 2.98 EPS for the current fiscal year.
Pfizer Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be paid a $0.43 dividend. The ex-dividend date is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a yield of 6.0%. Pfizer’s dividend payout ratio (DPR) is currently 226.32%.
About Pfizer
Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.
Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.
Further Reading
- Five stocks we like better than Pfizer
- Pathward’s Credit Scare Tests Its Comeback Story
- Wiring the AI Boom: Rumble’s $13.7B Pivot
- StoneX: Too Far Too Fast?
- DICK’s Sporting Goods Faces Pain Now for a Bigger Prize
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
